In the context of antibacterial drug discovery resurgence, novel therapeutic targets and new compounds with alternative mechanisms of action are of paramount importance. We focused on UDP-N-acetylenolpyruvylglucosamine reductase (i.e. MurB), an underexploited target enzyme that is involved in early steps of bacterial pepti- by MurA (Figure 1 ). MurB contains one molecule of noncovalently bound flavin adenine dinucleotide (FAD) that, during the catalytic process, serves as a hydride transfer mediator between β-nicotinamide dinucleotide phosphate (NADPH) and the enolpyruvyl substrate. First, NADPH binds to the enzyme and transfers the 4-pro-S hydrogen to N-5 atom of the enzyme-bound FAD, then NADP + dissociates from the enzyme. In the second half-reaction, substrate UDP-GlcNAc-EP binds to MurB with the following hydride transfer from FADH 2 to vinyl ether of the UDP substrate, forming UDP-N-acetyl muramic acid (UDP-MurNAc). [12] There are only few MurB inhibitors present in the literature and compounds 1 and 2 ( Figure 2 ) were amongst the first reported. Imidazolinone 2 is a result of optimization campaign where the heterocycle core replaced the starting 4-thiazolidinone moiety. Both heterocycles were designed to mimic the diphosphate moiety of UDP-GlcNAc-EP substrate. [13, 14] Compound 3 ( Figure 2 ) was identified by high-throughput (HTS) screening as MurB inhibitor with low micromolar K d value. [15] Furthermore, alkyl pyrazolidinedione derivatives were found as good inhibitors of Staphylococcus aureus and Escherichia coli MurB (e.g. Figure 2 ). [16, 17] A series of phenyl thiazolyl urea (e.g. 5, Figure 2 ) and carbamate analogues inhibited the enzyme in the low micromolar range. [18] Most published MurB inhibitors possessed promising antibacterial activities, however, when tested in the presence of 4% bovine serum albumin, their activities were lost, indicating high-protein binding properties of compounds. No novel inhibitors of MurB have been reported in the last decade, while the compounds described above were not pursued further due to their unfavourable physico-chemical properties. Therefore, we sought to identify novel compounds with improved physico-chemical properties and greater optimization potential. Overall, MurB is an attractive target in antibacterial drug discovery and herein we here report a successful pharmacophore-based insilico study that led to the discovery of novel structural class of MurB inhibitors.
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| METHODS AND MATERIALS
| Pharmacophore preparation and virtual screening
Protocol consisted of pharmacophore modelling, compound collection from ZINC version 12, database preparation and virtual screening. [19] Pharmacophore models can be described as representation or 3D-arrangement of the chemical features and steric limitations, postulated as necessary for a small molecule to interact with its target. [20] These features are presented in Figures 3 and 4 . MurB with non-covalently bound FAD and active site defined as space occupied by NADP (PDB IDs: 4JAY, 4JB1) was used in an automatic generation of three-dimensional structure-based pharmacophore using an effective LigandScout (Software-Entwicklungs und Consulting GmbH, Maria Enzersdorf, Austria) software package. Ten or less pharmacophoric features were used for pharmacophore generation with additional generation of exclusion volume spheres on the basis of available space at the active site. Resulting models are depicted in Figure 3 . [21] The created pharmacophore was validated with the superposition and analysis of MurB in complex with UDPGlcNAc-EP. [22] Upon structural analysis, NADP (PDB ID:
4JB1; Figure 4 ) presents the nicotinamide terminal moiety in the close proximity to the FAD flavin mononucleotide N-5 atom and Glu335 and Ser239 residues, consecutively enabling the transfer of hydride for the reduction of FAD. Similar positioning can be observed for the substrate UDP-GlcNAc-EP F I G U R E 1 Catalytic consecutive and two-step mechanism of MurB
F I G U R E 2 Previously described
MurB inhibitors present in the scientific literature (PDB ID: 2MBR) where the terminal carboxyvinyl moiety occupies the same space and the alkene fragment is positioned in close proximity to the N-5 atom of FAD(H 2 ) and Glu325 and Ser229 residues, for final substrate reduction towards UDP-MurNAc and NADP. Other terminus of both substrates diverged positionally, and uridine diphosphate or adenine diphosphate nucleotides were observed at distinct binding modes for UDP-GlcNAc-EP and NADP, respectively. Using LigandScout software, a three-dimensional pharmacophore for UDP-GlcNAc-EP in the active site was created, aligned to preceding pharmacophore model based on nicotinamide dinucleotide phosphate and a shared pharmacophore created, that is, pharmacophore where individual pharmacophoric elements are shared by multiple structures. The produced final shared 3D pharmacophore model was superimposed on the starting pharmacophore model and was found to be nearly identical apart from terminal H-bond donor/acceptor motif typical of terminal carboxamide (Figure 1, left) . [23] The final production pharmacophore model based on the MurB in complex with NADP + (PDB ID 4JAY) was thus refined by removing features, adjusting the tolerance sphere size and definition of exclusion spheres around the nicotinamide adenine dinucleotide phosphate ( Figure 4 ). Compounds were collected from ZINC 12 as Drugs Now subset (11,538,905 compounds) , and database for the virtual screening protocol was prepared with consecutive filtering steps. First, the database was checked for PAINS (pan-assay interference compounds) and known and predicted aggregators were filtered out using filter software from openeye (OpenEye Scientific Software, Inc., Santa Fe, NM, USA; www.eyesopen.com). [24, 25] Database was further pruned to eliminate structural faults, metals (metal complexes) and reactive functional groups that would pose frequent-hitter and high reactivity problems. [26] Molecules with molecular mass between 250 and 800 Da were retained to obtain a final collection of 4,755,936 compounds. Three-dimensional conformer database was prepared with openeye (OpenEye Scientific Software, Inc., Santa Fe, NM, USA; www.eyesopen.com) omega2 omega-fast pr ot ocol . Maximum number of conformations was set at 25, rms threshold of 0.8 was used and energy window of 10 with 4,000 max pool size with ring and nitrogen enumeration, molecules were used as reported in ZINC database without calculating all possible tautomer structures and ionizations. [27] Final LigandScout ldb database was created using idbgen software from Inte:Ligand (Software-Entwicklungs und Consulting GmbH, Maria Enzersdorf, Austria) ( Figure 5 ). Virtual screening was performed using Inte:Ligand LigandScout software with Pharmacophore-Fit scoring function. Exclusion spheres were considered in the calculation with minimum of three required pharmacophoric features. Top-ranked and commercially available compounds were purchased (Table 1 ) and biologically evaluated as described below. Amongst 12 purchased and biologically evaluated compounds, a hit compound 13 was identified, and IC 50 value was determined to be 34 μm on MurB.
| Molecular docking
Compounds were evaluated by filter 2.5.1.4 software (OpenEye Scientific Software, Inc., Santa Fe, NM, USA; www.eyesopen.com) for possible aggregation properties. 3D conformer library was generated with omega2 2.5.1.4 software from openeye with 3,000 maximum conformations per compound, rms of 0.5 and considered all possible stereoisomers of compounds. [27] Receptor was prepared from 
| Analogue identification
With the OpenBabel software, a path-based fingerprint FP2 which indexes linear fragments of up to seven atoms (similar to the Daylight fingerprints) was calculated for the main ZINC compound vendor catalogues (namely Enamine, ChemBridge, Vitas-M and Princeton Biomolecular Research) and fast search index created for the compound databases. Finally, the created databases were searched for compounds with similar chemical space to the query compound 13. [29] 2.4 | Cloning, overproduction and purification of MurB from E. coli
The E. coli murB gene was amplified from a DH5α strain (Invitrogen) using the primers 5′-GCGTGAATTCATGAAC CACTCCTTAAAACCC-3′ and 5′-CTACAAGCTTTCATG AAATTGTCTCCACTGCGC-3′. The primer upstream of the start codon (underlined) contained an engineered EcoRI site (in bold). The primer 3′ to the gene contained an engineered HindIII site (in bold). The amplified product was digested by EcoRI and HindIII and inserted between the compatible EcoRI and HindIII sites in vector pET2130 (T7 promoter), generating a plasmid that encodes MurB with a His 6 N-terminal extension. The construction was verified by DNA sequencing (Eurofins-MWG). Plasmid pET2130::murB Ec was transformed into E. coli BL21(DE3) (Novagen) for expression experiments. [30] An overnight preculture of E. coli BL21(DE3) harbouring pET2130::murB was used to inoculate 1 L of 2YT supplemented with 100 μg/ml ampicillin. The culture was incubated at 37°C with shaking until the optical density at 600 nm reached 0.8. Isopropyl β-d-thiogalactopyranoside was added at a final concentration of 1 mm, and incubation was continued for 3 hr at 37°C with shaking. The cells were harvested at 4°C, and the pellet was washed with cold 20 mm phosphate buffer, pH 7.2, containing 1 mm dithiothreitol (buffer A). Bacteria were resuspended in buffer A (10 ml) and disrupted by sonication in the cold. The resulting suspension was centrifuged at 4°C for 30 min at 200,000 g and the pellet was discarded. The supernatant was kept at -20°C. The His 6 -tagged MurB protein was purified on Ni 2+ -nitrilotriacetate-agarose following the manufacturer's recommendations (Qiagen). All procedures were performed at 4°C. The supernatant was mixed for 1 hr with the polymer, which had previously been washed with buffer A containing 0.3 m KCl and 10 mm imidazole. The washing and elution steps were performed with a discontinuous gradient of imidazole (20-300 mm) in buffer A containing 0.3 m KCl. Protein contents were analysed by sodium dodecyl sulphatepolyacrylamide gel electrophoresis. Relevant fractions were pooled and dialyzed against buffer A. Glycerol (10% final concentration) was added for storage of the protein at -20°C.
| MurB inhibition assay
The inhibition of MurB enzyme was measured with a continuous assay by monitoring the oxidation of NADPH. [30] The reaction mixture with final volume of 200 μl contained 50 mm Tris-HCl (pH 8.0), 10 mm KCl, 100 μm NADPH, 50 μm UDP-GlcNAc-EP and 100 μm of compound dissolved in DMSO. All of the compounds were soluble in the final assay mixture containing 2% of DMSO (v/v). The reaction was initiated by the addition of enzyme. The decrease in absorbance at 340 nm was monitored over 10 min at 37°C. The residual activity was calculated with respect to a similar assay without the inhibitors. All the experiments were performed in triplicates. The IC 50 values were determined at seven different concentrations of inhibitor and were calculated from the fitted regression equations using the logit-log plot. For the most active compound 30, Ki determinations were performed under similar assay conditions as described above. First, the concentrations of NADPH (25, 50, 75, 100 and 200 μm) were varied at fixed concentration of UDPGlcNAc-EP (50 μm). Then, the concentrations of UDPGlcNAc-EP (25, 50, 75 and 100 μm) were varied at fixed concentration of NADPH (100 μm). The concentrations of compounds 30 were 0, 10, 20, 30, 50, 75 and 100 μm. All experiments were performed in triplicates. The resulting data were analysed using the SigmaPlot 12 software and fitted to competitive, uncompetitive, non-competitive and mixed-type inhibition models. The mode of inhibition and Ki values were chosen from the best ranking model, as calculated by the software. A representative graph depicting the best fit model for compound 30 is shown in Figure 6 .
| Microbiological evaluation
The antimicrobial activities for compounds were determined by broth microdilution in Luria Broth Miller (LB) against S. aureus (ATCC 29213) and E. coli (ATCC 25922). All of the experiments were performed according to CLSI guidelines and European Committee for Antimicrobial Susceptibility Testing recommendations. [31] Bacterial suspension of specific bacterial strain equivalent to 0.5 McFarland turbidity standard (approximately 1 × 10 8 CFU/ml) was diluted with LB broth to obtain a final inoculum of 5 × 10 5 CFU/ml in the assay.
The compounds were dissolved in DMSO and then diluted 40-fold in LB, just before use. Bacterial suspension and test compound solution were mixed together in the 96-well plate (final volume, 200 μl) and incubated for 18-24 hr at 37°C. Optical density was measured at 600 nm and was used for evaluating the antimicrobial activity of tested compounds by comparing to untreated control. The MIC values were determined as the lowest dilutions of the compounds showing no turbidity.
| Reagents and analytics
All of the chemicals used were obtained from commercial sources (Acros, Aldrich, Alfa Aeser, Fluka) and were used without further purification. Solvents were used without purification or drying, unless otherwise stated. Reactions were monitored using analytical thin-layer chromatography plates (Merck, silica gel 60 F254, 0.25 mm), and the compounds were visualized with ultraviolet light and ninhydrin staining reagent. Silica gel grade 60 (particle size 0.040-0.063 mm; Merck, Germany) was used for flash-column chromatography.
H and 13
C NMR spectra were recorded on a Bruker AVANCE III 400 MHz spectrometer in CDCl 3 and DMSO-d 6 solvents, respectively, with TMS as the internal standard. Mass spectra were obtained with a VG-Analytical Autospec Q mass spectrometer (Centre for Mass Spectrometry, Institute Jožef Stefan, Ljubljana). Melting points were determined using a Reichert hot-stage microscope and are uncorrected. HPLC analyses were performed on a Thermo Scientific Dionex UltiMate 3000 system (Thermo Fisher Scientific Inc., Waltham, MA, USA), using an Agilent Eclipse Plus C18 column (5 μm, 4.6 × 150 mm), at a flow rate of 1.5 ml/min, temperature 25°C and injection volume of 10 μl. The eluent was a mixture of 0.1% TFA in water (A) and acetonitrile (B). The gradient was 10% B to 90% B in 15 min, then 90% B for 5 min. The purity of the tested compounds was established to be ≥95%.
| Chemistry
Hit compound 13 ( Table 2 ) was resynthesized along with four additional compounds (18, 24, 25 and 30; Table 2 ). Key 5-(4-chlorophenyl)-1H-tetrazole intermediate 13a ( Figure 7 ) was prepared by the treatment of nitrile with sodium azide and ammonium chloride. N-Chloroacetamides were synthesized from different anilines and chloroacetyl chloride. All 2,5-disubstituted tetrazoles were obtained from N-chloroacetamides and tetrazole in ethanol in the presence of KOH. Finally, nitriles were converted to amides using alkaline hydrogen peroxide (Figure 7 ). [32] 
| 5-(4-Chlorophenyl)-1H-tetrazole (13a)
To a solution of 4-chlorobenzonitrile (3.0 g, 21.8 mmol) in DMF (15 ml), NaN 3 (1.56 g, 24.0 mmol) and NH 4 Cl (1.28 g, 24 mmol) were added. The reaction mixture was stirred at 120°C for 16 hr. The mixture was cooled to room temperature, and 1 m HCl (50 ml) was added. 
| General procedure for synthesis of compounds 24a, 25a and 30a
To a solution of different anilines (8.5 mmol) in DCM (25 ml), TEA (2.35 ml, 16.9 mmol) was added and the mixture was cooled to 0°C. Chloroacetyl chloride (0.750 ml, 9.35 mmol) diluted in DCM (10 ml) was added dropwise, and the mixture was stirred for 6 hr at room temperature. To the reaction mixture, DCM (50 ml) was added and it was washed with water (50 ml), 1 m HCl (2 × 50 ml), saturated aqueous NaHCO 3 (50 ml) and brine (50 ml), dried with Na 2 SO 4 and evaporated under reduced pressure. The solid was used without further purification. 
2-Chloro-N-(3-cyanophenyl)acetamide (24a)
2-Chloro-N-(4-cyanophenyl)acetamide (25a)
2-Chloro-N-phenylacetamide (30a)
Yield = 73%; mp = 138-141°C (lit. 136-139°C [32] ) 
| General procedure for synthesis of compounds 24, 25 and 30
To a solution of KOH (3.75 mmol) in ethanol (20 ml), 5-(4-chlorophenyl)-1H-tetrazole (2.5 mmol) and chloroacetamides (24a, 25a or 30a, 2.5 mmol) were added and the mixture was heated under reflux for 16 hr. The reaction was cooled to room temperature and water (50 ml) was added. The formed precipitate was filtered off and recrystallized from ethanol to obtain pure final compounds.
2-(5-(4-Chlorophenyl)-2H-tetrazol-2-yl)-N-(3-cyanophenyl)acetamide (24)
Yield = 51%; white solid, mp = 209-211°C; 1 t R = 10.183 min (99% at 254 nm).
2-(5-(4-Chlorophenyl)-2H-tetrazol-2-yl)-N-(4-cyanophenyl)acetamide (25)
Yield = 46%; white solid, mp = 228-230°C; 1 
2-(5-(4-Chlorophenyl)-2H-tetrazol-2-yl)-Nphenylacetamide (30)
Yield = 58%; white needles, mp = 210-212°C; 
| General procedure for synthesis of compounds 13 and 18
To a cooled (0°C) solution of nitrile (0.080 mg, 0.236 mmol) in DMSO, 30% H 2 O 2 (0.5 ml) and 1 m NaOH were added (0.70 ml, 0.700 mmol). The reaction mixture was stirred for 4 hr at room temperature. It was quenched with saturated aqueous Na 2 SO 3 . The formed precipitate was washed with water and recrystallized from ethanol to obtain pure final compounds. 
3-(2-(5-(4-Chlorophenyl)-2H-tetrazol-2-yl)acetamido
| RESULTS AND DISCUSSION
| Virtual screening
Pharmacophore models are widely used as virtual screening filters and can be applied in ligand-based and structure-based design scenarios where compound databases are mapped to the pharmacophore model and key interactions are postulated for the hits of such VS studies. [33] With the help of recently available crystal structure information on MurB enzyme in complex with NADP + (PDB IDs: 4JAY, 4JB1) and available enzymatic data on MurB in complex with the substrate UDPGlcNAc-EP (PDB ID: 2MBR), the pharmacophore model was designed in a mixed ligand-based and structure-based manner.
The pharmacophore model was used in a subsequent filtering step where previously curated ZINC-based LigandScout ldb conformer database was screened to identify an initial hit compound 13. The details are described in Section 2.
| Ligand-based drug design and biological evaluation
As the hit compound 13 showed promising inhibitory activity in low micromolar range (IC 50 value of 34 μm), additional in silico analogue identification step was performed. From the compounds with highest similarity to 13, available compounds 19-23 and 26-29 were obtained as presented in Table 2 . Furthermore, we have decided to resynthesize VS screening hit 13 and to synthesize additional compounds 18, 24, 25 and 30 to analytically validate the studied structures and perform an initial structure-activity relationship study on the tetrazole compound set ( [17] where structurally similar series of pyrazolidine-3,5-dione inhibitors of MurB roughly occupied the same pocket above the FAD N-5 atom with the para-chlorophenyl moiety.
The steady-state analysis of enzyme kinetics was performed for the most potent compound 30. The best model revealed non-competitive binding of inhibitor with respect to NADPH, with Ki value of 63 ± 10 μm. The models of inhibition with respect to UDP-GlcNAc-EP showed no correlation. The positive control (compound 5) was evaluated under the same conditions as our compounds, and it inhibited MurB with an IC 50 value of 20 ± 2 μm (literature value 11.4 μm). [18] 
| Molecular docking
Compounds 25, 18, 22, 30, 26 and 13 were the highest ranking and all shared similar predicted binding mode (Figure 8c ). The polar tetrazole core occupies the space of triphosphopyridine nucleotide sugar and phosphate, extending with the acetamido moiety towards the FAD N-5 atom, and Glu335 and Ser239 residues. Terminal para-chlorophenyl ring attached to the position 5 of the tetrazole core is favourable for inhibitory activity as relocation or substitution of chlorine atom led to inactive compounds. Similar observation was interestingly also reported by Gilbert et al. [17] in the study of structurally similar series of pyrazolidine-3,5-dione inhibitors of MurB. For reference, pyrazolidine-3,5-dione compound 7f (Figure 8c ) reported by Kutterer et al. was also docked in our system where similar binding mode to tetrazole compounds was observed (Figure 8c ). Contrasting to para-chlorophenyl compounds, relocation of chlorine to ortho-position on phenyl ring or substitution of chlorine atom with orthomethyl substituent resulted in a slightly altered binding mode according to our molecular docking study. It can be postulated that π-π stacking of para-chlorophenyl moiety between Tyr196 and Tyr264 residues is favourable with additional interactions between ligand tetrazol-acetamido central moiety towards Asn243 and Lys272 (Figure 8b ). Reported inhibitor 7f by Kutterer et al. branches the scaffold with additional para-chlorophenyl moiety that extends towards Asn243, but our reported tetrazoles can favourably reach deeper in the main pocket towards FAD, where a carboxamide or similar functional group can interact with FAD. Compounds could be therefore described as structural continuation of 1,2-bis(4-chlorophenyl) pyrazolidine-3,5-diones reported beforehand. [16] We also compared the docked poses of our tetrazole compounds and aligned them to the starting pharmacophore model. We observed a good correlation between common binding mode of tetrazole compounds and essential structural features imposed by the starting pharmacophore model used in VS scenario (Figure 8d ).
| CONCLUSIONS
In conclusion, a novel series of 5-substituted tetrazol-2-yl acetamido inhibitors of MurB have been identified through combined structure-based and ligand-based drug design methods. Several low micromolar inhibitors have been reported with compounds 13 (Figure 8a ), 26 and 30 displaying IC 50 values of 34, 28 and 25 μm, respectively. If none of the tested compounds possessed in vitro antimicrobial activity against S. aureus and E. coli, the reported series nevertheless lends itself to further optimization studies as similar scaffolds are reported in literature bearing antibacterial activity. [34] Furthermore, reported series is also of interest for biological evaluation of the compound effects on bacterial virulence. After a thorough analysis of the research field, this study is relevant in the context of antibacterial drug discovery, as there were few inhibitors reported up to date. Additional studies would enable further structure-activity relationship data, experimental insight into the binding modes and possible optimization towards antibacterial activity.
